2014年11月27日 · Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50 s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC 50 s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy …

SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-imidazole) is a selective inhibitor of p38 MAPK. This compound inhibits the activation of MAPKAPK-2 by p38 MAPK and subsequent phosphorylation of HSP27 (9).

SB203580 is a high purity inhibitor widely used to study the role of p38 mitogen-activated protein (MAP) kinase. SB203580 inhibits also the phosphorylation and activation of protein kinase B (PKB, also known as Akt).

2008年9月28日 · We show that SB203580 activates ERK and JNK in primary cultures of human hepatocytes. The levels of ERK-P(Thr202/Tyr204), JNK-P(Thr183/Tyr185) and c-Jun-P(Ser63/73), a target down-stream protein of JNK, were increased by SB203580.

SB203580 (Hydrochloride) is a potent inhibitor of p38 MAPK activity (IC₅₀ = 0.6 µM). It inhibits both the α and β isoforms of p38 MAPK, and does not inhibit ERK or JNK. (Bain et al., Cuenda et al.) · Enhances the growth and self-renewal of mouse embryonic stem (ES) cells (Qi et al.).

SB203580 is a pyridinyl imidazole inhibitor widely used to study the role of p38 mitogen-activated protein kinase (MAPK)1. p38 MAPKs are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in cell differentiation, apoptosis, and autophagy.

SB 203580 is a pyridinyl imidazole that suppresses the activation of MAPKAP kinase-2 and inhibits the phosphorylation of heat shock protein (HSP) 27 in response to IL-1, cellular stresses and bacterial endotoxin in vivo.

2014年1月21日 · Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50 s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC 50 s of 100-500-fold higher than that for SAPK2a/p38.